ARMANI: Ramucirumab Plus Paclitaxel as Switch Maintenance for Advanced HER2-Negative Gastric/GEJ Cancer
By Filippo Pietrantonio, MD, Nataliya Uboha, MD, PhD - Last Updated: March 19, 2025Filippo Pietrantonio, MD, of IRCCS Istituto Nazionale dei Tumori, and Nataliya Uboha, MD, PhD, of University of Wisconsin School of Medicine and Public Health, break down the results of the phase 3 ARMANI trial.
Advertisement
The trial investigated ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction cancer.
View their continued comments on OS Date From CodeBreaK 300 for KRAS G12C-Mutated mCRC.
Advertisement
Related Posts
Circulating tumor DNA burden in patients with gastric cancer may aid oncologists in determining treatment options.
Dr. Cytryn considers two studies evaluating PD-1 inhibition in patients with MSI-high tumors in the locally advanced setting.
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Of subtypes in KEYNOTE-059 and -061, HRD scores and TMB were highest in CIN and MSI-H subtypes, respectively.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.